SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): June 9, 2004
ARIAD PHARMACEUTICALS, INC.
---------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 5. OTHER EVENTS
On June 9, 2004, the Registrant disseminated a Press Release
announcing that it will host a conference call for biotechnology
investment analysts on Tuesday, June 15, 2004, at 11:00 a.m. (ET).
The Company's senior management will discuss the highlights of the
up-to-date clinical results of its lead oncology product candidate,
AP23573, which were summarized in a press release issued June 7, and
its plans for advancing the clinical development of this product
candidate, which will be released before the market opens on June 15.
The information contained in the Press Release dated June 9, 2004, is
incorporated herein by reference and attached as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated June 9, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
--------------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: June 9, 2004
EXHIBIT INDEX
-------------
Exhibit
Number Description Sequential Page Number
- ------- ----------- ----------------------
99.1 The Registrant's Press Release dated 4
June 9, 2004.